Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors

被引：15

作者：

Hammel, Pascal ^{[1
]}

Vitellius, Carole ^{[2
,3
,4
]}

Boisteau, Emeric ^{[5
,6
]}

Wisniewski, Mathilde ^{[7
,8
]}

Colle, Elise ^{[7
,8
]}

Hilmi, Marc ^{[9
]}

Dengremont, Christelle ^{[10
,11
]}

Granier, Sandra ^{[12
]}

Turpin, Anthony ^{[13
]}

de Mestier, Louis ^{[8
,14
]}

Neuzillet, Cindy ^{[15
]}

机构：

[1] Univ Paris, Hop Beaujon, AP HP, Digest Oncol, 100 Blvd Leclerc, F-92110 Clichy, France

[2] CHU Angers, Gastroenterol & Digest Oncol, Angers, France

[3] CHU Angers, Lab HIFIH UPRES EA 3859, SFR 4208, Angers, France

[4] Univ Angers, Angers, France

[5] CHU Pontchaillou, Gastroenterol & Hepatol, Rennes, France

[6] Univ Rennes, Rennes, France

[7] Hop Beaujon, AP HP, Digest Oncol, Clichy, France

[8] Univ Paris, Clichy, France

[9] Univ Paris Saclay, Gustave Roussy Canc Campus Grand Paris, Gastrointestinal Oncol Unit, Villejuif, France

[10] CHU La Tronche, Hepatogastroenterol Unit, Grenoble, France

[11] Univ Grenoble, Grenoble, France

[12] Grp Hosp St Joseph, Med Oncol, Paris, France

[13] Lille Univ Hosp, Med Oncol, Lille, France

[14] Hop Beaujon, AP HP, Gastroenterol & Pancreatol, Clichy, France

[15] Versailles St Quentin Univ, Inst Curie St Cloud, Med Oncol Dept, GI Oncol, St Cloud, France

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2020年 / 12卷

关键词：

chemotherapy; FOLFIRINOX; gemcitabine; maintenance; nab-paclitaxel; olaparib; pancreatic cancer; PARP; quality of life; toxicity; ADENOCARCINOMA; GEMCITABINE; MUTATION; GO; MULTICENTER; CISPLATIN; SURVIVAL; TRIAL;

D O I：

10.1177/1758835920937949

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Metastatic pancreatic ductal adenocarcinomas (PDACs) are now more effectively controlled using chemotherapy combinations such as FOLFIRINOX and gemcitabine plus nab-paclitaxel (NabP) regimens with a subset of patients who achieve a sustained tumor stabilization or response. The next challenge is to design maintenance therapies that result in continued tumor control with minimal toxicity. Quality of life should always be a priority in these patients with prolonged survival. Gradually tapering off the intensity of chemotherapy by suppressing drug(s) in the combination is one option. Thus, maintenance with 5-fluorouracil or gemcitabine as single agents after FOLFIRINOX or gemcitabine-NabP induction, respectively, seems to be a promising approach to minimize neurotoxicity while maintaining efficacy. Another option is to introduce maintenance drug(s) with different anti-tumoral actions. The recent example of olaparib in patients with BRCA mutated PDAC provides a promising proof-of-concept of a switch maintenance strategy in this setting.

引用

页数：9

共 44 条

[1] A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2, PALB2 [J].

Binder, Kim A. Reiss ;

Mick, Rosemarie ;

O'Hara, Mark ;

Teitelbaum, Ursina ;

Karasic, Thomas ;

Schneider, Charles ;

O'Dwyer, Peter J. ;

Carpenter, Erica ;

Pantel, Austin ;

Makvandi, Mehran ;

Mankoff, David ;

Nathanson, Katherine ;

Maxwell, Kara ;

Cowden, Stacy ;

Fuhrer, Mary Jane ;

Romeo, Janae ;

Beatty, Gregory L. ;

Domchek, Susan .

CANCER RESEARCH, 2019, 79 (13)

[2] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].

Burris, HA ;

Moore, MJ ;

Andersen, J ;

Green, MR ;

Rothenberg, ML ;

Madiano, MR ;

Cripps, MC ;

Portenoy, RK ;

Storniolo, AM ;

Tarassoff, P ;

Nelson, R ;

Dorr, FA ;

Stephens, CD ;

VanHoff, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413

[3] Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma [J].

Connor, Ashton A. ;

Denroche, Robert E. ;

Jang, Gun Ho ;

Timms, Lee ;

Kalimuthu, Sangeetha N. ;

Selander, Iris ;

McPherson, Treasa ;

Wilson, Gavin W. ;

Chan-Seng-Yue, Michelle A. ;

Borozan, Ivan ;

Ferretti, Vincent ;

Grant, Robert C. ;

Lungu, Ilinca M. ;

Costello, Eithne ;

Greenhalf, William ;

Palmer, Daniel ;

Ghaneh, Paula ;

Neoptolemos, John P. ;

Buchler, Markus ;

Petersen, Gloria ;

Thayer, Sarah ;

Hollingsworth, Michael A. ;

Sherker, Alana ;

Durocher, Daniel ;

Dhani, Neesha ;

Hedley, David ;

Serra, Stefano ;

Pollett, Aaron ;

Roehrl, Michael H. A. ;

Bavi, Prashant ;

Bartlett, John M. S. ;

Cleary, Sean ;

Wilson, Julie M. ;

Alexandrov, Ludmil B. ;

Moore, Malcolm ;

Wouters, Bradly G. ;

McPherson, John D. ;

Notta, Faiyaz ;

Stein, Lincoln D. ;

Gallinger, Steven .

JAMA ONCOLOGY, 2017, 3 (06) :774-783

[4] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].

Conroy, Thierry ;

Desseigne, Francoise ;

Ychou, Marc ;

Bouche, Olivier ;

Guimbaud, Rosine ;

Becouarn, Yves ;

Adenis, Antoine ;

Raoul, Jean-Luc ;

Gourgou-Bourgade, Sophie ;

de la Fouchardiere, Christelle ;

Bennouna, Jaafar ;

Bachet, Jean-Baptiste ;

Khemissa-Akouz, Faiza ;

Pere-Verge, Denis ;

Delbaldo, Catherine ;

Assenat, Eric ;

Chauffert, Bruno ;

Michel, Pierre ;

Montoto-Grillot, Christine ;

Ducreux, Michel .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825

[5] FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX). [J].

Dahan, Laetitia ;

Phelip, Jean Marc ;

Le Malicot, Karine ;

Williet, Nicolas ;

Desrame, Jerome ;

Volet, Julien .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[6] Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers [J].

de Mestier, Louis ;

Danset, Jean-Baptiste ;

Neuzille, Cindy ;

Rebours, Vinciane ;

Cros, Jerome ;

Soufir, Nadem ;

Hammel, Pascal .

[7] How to treat pancreatic adenocarcinoma in elderly: How far can we go in 2017? [J].

Gilabert, Marine ;

Raoul, Jean Luc ;

Rousseau, Frederique .

JOURNAL OF GERIATRIC ONCOLOGY, 2017, 8 (06) :407-412

[8]

Golan T, 2019, NEW ENGL J MED, V377, P523

[9] Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial [J].

Golan, Talia ;

Kindler, Hedy L. ;

Park, Joon Oh ;

Reni, Michele ;

Macarulla, Teresa ;

Hammel, Pascal ;

Van Cutsem, Eric ;

Arnold, Dirk ;

Hochhauser, Daniel ;

McGuinness, David ;

Locker, Gershon Y. ;

Goranova, Teodora ;

Schatz, Philipp ;

Liu, Yu-Zhen ;

Hall, Michael J. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (13) :1442-+

[10] Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib [J].

Hammel, P. ;

Kindler, H. L. ;

Reni, M. ;

Van Cutsem, E. ;

Macarulla, T. ;

Hall, M. J. ;

Park, J. O. ;

Hochhauser, D. ;

Arnold, D. ;

Oh, D-Y ;

Reinacher-Schick, A. ;

Tortora, G. ;

Alguel, H. ;

O'Reilly, E. M. ;

McGuinness, D. ;

Cui, K. Y. ;

Joo, S. ;

Yoo, H. K. ;

Patel, N. ;

Golan, T. ;

Chantrill, Lorraine ;

Goldstein, David ;

Joubert, Warren ;

Pavlakis, Nick ;

Tognela, Annette ;

Van Cutsem, Eric ;

Van Fraeyenhove, Frank ;

Van Laethem, Jean-Luc ;

Peeters, Marc ;

Dhani, Neesha ;

Kavan, Petr ;

Lemay, Frederic ;

Adenis, Antoine ;

Artru, Pascal ;

Hamed, Nabil ;

Belletier, Christine ;

Ben Abdelghani, Meher ;

Blanc, Jean-Frederic ;

Borg, Christophe ;

Coriat, Romain ;

Deplanque, Gael ;

Faroux, Roger ;

Follana, Philippe ;

Guimbaud, Rosine ;

el Hajbi, Farid ;

Hammel, Pascal ;

Hautefeuille, Vincent ;

Malka, David ;

Metges, Jean-Philippe ;

Tougeron, David .

ANNALS OF ONCOLOGY, 2019, 30 (12) :1959-1968

← 1 2 3 4 5 →